266 related articles for article (PubMed ID: 16290155)
1. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M
Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155
[TBL] [Abstract][Full Text] [Related]
2. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
[TBL] [Abstract][Full Text] [Related]
3. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
4. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
[TBL] [Abstract][Full Text] [Related]
5. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
6. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
7. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
Pedersen M; Rasmussen BB
Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
[TBL] [Abstract][Full Text] [Related]
8. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
Pathol Int; 2005 Jun; 55(6):318-23. PubMed ID: 15943788
[TBL] [Abstract][Full Text] [Related]
9. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
10. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
Sartelet H; Lagonotte E; Lorenzato M; Duval I; Lechki C; Rigaud C; Cucherousset J; Durlach A; Graesslin O; Abboud P; Doco-Fenzy M; Quereux C; Costa B; Polette M; Munck JN; Birembaut P
J Clin Pathol; 2005 Aug; 58(8):864-71. PubMed ID: 16049291
[TBL] [Abstract][Full Text] [Related]
11. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
Lin F; Shen T; Prichard JW
Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
[TBL] [Abstract][Full Text] [Related]
13. Evaluating HER2 amplification and overexpression in breast cancer.
Bartlett JM; Going JJ; Mallon EA; Watters AD; Reeves JR; Stanton P; Richmond J; Donald B; Ferrier R; Cooke TG
J Pathol; 2001 Nov; 195(4):422-8. PubMed ID: 11745673
[TBL] [Abstract][Full Text] [Related]
14. Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH).
Fischer I; de la Cruz C; Rivera AL; Aldape K
Diagn Mol Pathol; 2008 Dec; 17(4):227-30. PubMed ID: 18382350
[TBL] [Abstract][Full Text] [Related]
15. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
Isola J; Tanner M; Forsyth A; Cooke TG; Watters AD; Bartlett JM
Clin Cancer Res; 2004 Jul; 10(14):4793-8. PubMed ID: 15269154
[TBL] [Abstract][Full Text] [Related]
16. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
Laakso M; Tanner M; Isola J
J Pathol; 2006 Sep; 210(1):3-9. PubMed ID: 16823892
[TBL] [Abstract][Full Text] [Related]
17. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A
Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
[TBL] [Abstract][Full Text] [Related]
18. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
Bhargava R; Lal P; Chen B
Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
[TBL] [Abstract][Full Text] [Related]
19. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
20. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.
Madrid MA; Lo RW
Breast Cancer Res; 2004; 6(5):R593-600. PubMed ID: 15318940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
